Hemab Therapeutics Holdings, Inc. (COAG)
| Market Cap | 1.84B |
| Revenue (ttm) | n/a |
| Net Income | -93.47M |
| EPS | -4.72 |
| Shares Out | 46.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 347,014 |
| Open | 39.50 |
| Previous Close | 39.86 |
| Day's Range | 38.77 - 40.19 |
| 52-Week Range | 23.00 - 55.42 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 63.00 (+60.35%) |
| Earnings Date | Nov 10, 2026 |
About COAG
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for COAG stock is "Strong Buy." The 12-month stock price target is $63.0, which is an increase of 60.35% from the latest price.
News
Hemab Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference
Sutacimig is in Phase III for GT, while Factor VII deficiency data are expected at ASH. VWD data are due in February, HMB-003 data in mid-2027, and cash runway extends well into 2029.
Hemab Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment ...
Hemab Therapeutics Holdings Earnings Call Transcript: Q3 2026
Q3 loss widened as R&D and G&A increased, with $430.2M in cash and runway into 2029. SOLARA began for Glanzmann thrombasthenia, while clinical updates across all three programs are expected through February 2027.
Hemab Therapeutics Holdings Earnings release: Q3 2026
Hemab Therapeutics Holdings released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Hemab Therapeutics Holdings Quarterly report: Q3 2026
Hemab Therapeutics Holdings has published its Q3 2026 quarterly earnings report on November 10, 2026.
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-0...
Hemab Therapeutics initiates SOLARA trial
Hemab Therapeutics (COAG) announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig as a potential prophylactic treatment for people with Glanzmann thrombasthenia, or GT. The fi...
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Hemab's first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia
Hemab Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $65 price target
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial p...
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment ...
Hemab Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Joyce Zhou initiated coverage of Hemab Therapeutics (COAG) with an Overweight rating and $70 price target The firm says the company has an emerging pipeline of early to…
Hemab Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $56 price target The firm cites sutacimig’s path to becoming the first approved prophylactic therapy in…
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of...
Hemab Therapeutics doses first patient in HMB-003 trial
Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual b...
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care f...
Hemab Therapeutics price target raised to $64 from $55 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Hemab Therapeutics (COAG) to $64 from $55 and keeps an Outperform rating on the shares. The firm notes the company…
Hemab Therapeutics Holdings Slides: Corporate presentation
Hemab Therapeutics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Hemab Therapeutics price target raised to $60 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Hemab Therapeutics (COAG) to $60 from $52 and keeps a Buy rating on the shares post the Q2 report. The firm says…
Hemab Therapeutics Holdings Earnings release: Q2 2026
Hemab Therapeutics Holdings released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Hemab Therapeutics Holdings Quarterly report: Q2 2026
Hemab Therapeutics Holdings has published its Q2 2026 quarterly earnings report on August 11, 2026.
Hemab Therapeutics presents sutacimig data at ISTH Congress
Hemab Therapeutics (COAG) presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis, or ISTH, 2026 Congress in Paris, France. Th...
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
Hemab Therapeutics price target raised to $47 from $39 at Jefferies
Jefferies raised the firm’s price target on Hemab Therapeutics (COAG) to $47 from $39 and keeps a Buy rating on the shares after competitor Incyte’s (INCY) Star unit reported additional…
Hemab Therapeutics price target raised to $55 from $42 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Hemab Therapeutics (COAG) to $55 from $42 and keeps an Outperform rating on the shares. HMB-002 showed promising clinical data…